RDI was founded in 2001.
As a private company, we focus on incubating projects in four crucial sectors:
Environment, Cancer, Radiation, and Space.
Space Health Innovation
We develop medical countermeasures to protect health and enhance safety of humans deliberately or accidentally exposed to ionizing radiation. These innovations are crucial for addressing the unique challenges faced by cancer patients treated with radiotherapies, health professionals, first responders, and astronauts, working in hazardous environments.
Cancer Research Initiatives
Our portfolio includes compounds designed to offer protection of off-target/healthy tissues from radiation, enhancing the safety and efficacy of radiotherapy for cancer treatment on Earth.
Environmental Remediation Initiatives
We lead efforts to remediate environments contaminated with radionuclides, heavy metals, PFAS, aiming to restore ecosystems and protect public health.
At RDI, we are dedicated to enhancing the well-being of astronauts, and improving therapeutic outcomes for cancer patients globally.
Our commitment transcends terrestrial applications as we continue to lead in the realms of space research, clinical oncology, and environmental restoration.
Management Team
Stig Løfberg
CEO
Prof. Svend Aage Engelholm
CMO
S. Pigarev
CTO
Prof. Stig Larsen
Clinical Research
MD, Alla Shapiro
Radiation Medical Countermeasures
Beth Carino
Business Development